Eve E. Kelland
Contact
Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis Front Immunol. 2021; 12:706278. . View in PubMed
Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis J Neuroinflammation. 2020 Jun 15; 17(1):189. . View in PubMed
Activation of the Protective Arm of the Renin Angiotensin System in Demyelinating Disease J Neuroimmune Pharmacol. 2020 06; 15(2):249-263. . View in PubMed
Reduced disease severity following therapeutic treatment with angiotensin 1-7 in a mouse model of multiple sclerosis Neurobiol Dis. 2019 07; 127:87-100. . View in PubMed
The influence of retinoic acid on the human oligodendrocyte precursor cells by RNA-sequencing Biochem Biophys Rep. 2017 Mar; 9:166-172. . View in PubMed
In vitro assessment of the direct effect of laquinimod on basic functions of human neural stem cells and oligodendrocyte progenitor cells J Neurol Sci. 2014 Nov 15; 346(1-2):66-74. . View in PubMed
Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod J Neuroimmunol. 2013 Oct 15; 263(1-2):108-15. . View in PubMed
The dual role of CXCL8 in human CNS stem cell function: multipotent neural stem cell death and oligodendrocyte progenitor cell chemotaxis Glia. 2011 Dec; 59(12):1864-78. . View in PubMed
The geometric and spatial constraints of the microenvironment induce oligodendrocyte differentiation Proc Natl Acad Sci U S A. 2008 Sep 23; 105(38):14662-7. . View in PubMed
Measuring apoptosis in neural stem cells Methods Mol Biol. 2008; 438:227-41. . View in PubMed
Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist Neuropharmacology. 2004 Jul; 47(1):46-64. . View in PubMed
Pyruvate limits zinc-induced rat oligodendrocyte progenitor cell death Eur J Neurosci. 2004 Jan; 19(2):287-94. . View in PubMed
Characterisation of zinc uptake into rat cultured cerebrocortical oligodendrocyte progenitor cells Neurosci Lett. 2003 Dec 04; 352(2):113-6. . View in PubMed
Regional mapping of low-affinity kainate receptors in mouse brain using [(3)H](2S,4R)-4-methylglutamate autoradiography Eur J Pharmacol. 2001 Nov 23; 431(3):305-10. . View in PubMed
Group I metabotropic glutamate receptors limit AMPA receptor-mediated oligodendrocyte progenitor cell death Eur J Pharmacol. 2001 Jul 27; 424(3):R3-4. . View in PubMed
Dr. Kelland has received grant support from the Race to Erase MS, the USC Medical Faculty Women's Association, the SC-CTSI and the Zumberge Foundation. Current research projects in Dr. Kelland’s laboratory focus on defining the effect of chemokines and chemokine receptors on the potential for neural stem cells and oligodendrocyte progenitor cells to repair types of neural damage that occur in multiple sclerosis (MS) as well as the role of the renin-angiotensin system in MS disease pathogenesis. Additional projects in Dr. Kelland’s laboratory involve the study of new drugs for MS, and whether they affect the ability of neural stem cells and oligodendrocyte progenitor cells to repair neural damage.